Your browser doesn't support javascript.
Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia.
Kanter, Katie; Gallagher, Ryan; Eweje, Feyisope; Lee, Alexander; Gordon, David; Landy, Stephen; Gasior, Julia; Soto-Calderon, Haideliza; Cronholm, Peter F; Cocchiaro, Ben; Weimer, James; Roth, Alexis; Lankenau, Stephen; Brenner, Jacob.
  • Kanter K; Perelman School of Medicine, University of Pennsylvania, 3450 Hamilton Walk, Stemmler Building, Office #220, Philadelphia, PA, 19104, USA.
  • Gallagher R; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
  • Eweje F; Perelman School of Medicine, University of Pennsylvania, 3450 Hamilton Walk, Stemmler Building, Office #220, Philadelphia, PA, 19104, USA.
  • Lee A; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
  • Gordon D; Perelman School of Medicine, University of Pennsylvania, 3450 Hamilton Walk, Stemmler Building, Office #220, Philadelphia, PA, 19104, USA.
  • Landy S; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
  • Gasior J; Perelman School of Medicine, University of Pennsylvania, 3450 Hamilton Walk, Stemmler Building, Office #220, Philadelphia, PA, 19104, USA.
  • Soto-Calderon H; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
  • Cronholm PF; Ballinger, 833 Chestnut Street, Suite 1400, Philadelphia, PA, 19107, USA.
  • Cocchiaro B; Perelman School of Medicine, University of Pennsylvania, 3450 Hamilton Walk, Stemmler Building, Office #220, Philadelphia, PA, 19104, USA.
  • Weimer J; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
  • Roth A; Perelman School of Medicine, University of Pennsylvania, 3450 Hamilton Walk, Stemmler Building, Office #220, Philadelphia, PA, 19104, USA.
  • Lankenau S; Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA.
  • Brenner J; Penn Department of Medicine Clinical Trials Unit, Anatomy-Chemistry Building, 1st Floor, Philadelphia, PA, 19104, USA.
Harm Reduct J ; 18(1): 75, 2021 07 23.
Article in English | MEDLINE | ID: covidwho-1322939
ABSTRACT

BACKGROUND:

The incidence of opioid-related overdose deaths has been rising for 30 years and has been further exacerbated amidst the COVID-19 pandemic. Naloxone can reverse opioid overdose, lower death rates, and enable a transition to medication for opioid use disorder. Though current formulations for community use of naloxone have been shown to be safe and effective public health interventions, they rely on bystander presence. We sought to understand the preferences and minimum necessary conditions for wearing a device capable of sensing and reversing opioid overdose among people who regularly use opioids.

METHODS:

We conducted a combined cross-sectional survey and semi-structured interview at a respite center, shelter, and syringe exchange drop-in program in Philadelphia, Pennsylvania, USA, during the COVID-19 pandemic in August and September 2020. The primary aim was to explore the proportion of participants who would use a wearable device to detect and reverse overdose. Preferences regarding designs and functionalities were collected via a questionnaire with items having Likert-based response options and a semi-structured interview intended to elicit feedback on prototype designs. Independent variables included demographics, opioid use habits, and previous experience with overdose.

RESULTS:

A total of 97 adults with an opioid use history of at least 3 months were interviewed. A majority of survey participants (76%) reported a willingness to use a device capable of detecting an overdose and automatically administering a reversal agent upon initial survey. When reflecting on the prototype, most respondents (75.5%) reported that they would wear the device always or most of the time. Respondents indicated discreetness and comfort as important factors that increased their chance of uptake. Respondents suggested that people experiencing homelessness and those with low tolerance for opioids would be in greatest need of the device.

CONCLUSIONS:

The majority of people sampled with a history of opioid use in an urban setting were interested in having access to a device capable of detecting and reversing an opioid overdose. Participants emphasized privacy and comfort as the most important factors influencing their willingness to use such a device. TRIAL REGISTRATION NCT04530591.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Acceptance of Health Care / Wearable Electronic Devices / Opiate Overdose / Naloxone / Narcotic Antagonists Type of study: Diagnostic study / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Adolescent / Adult / Child / Female / Humans / Male / Young adult Country/Region as subject: North America Language: English Journal: Harm Reduct J Year: 2021 Document Type: Article Affiliation country: S12954-021-00522-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Acceptance of Health Care / Wearable Electronic Devices / Opiate Overdose / Naloxone / Narcotic Antagonists Type of study: Diagnostic study / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Adolescent / Adult / Child / Female / Humans / Male / Young adult Country/Region as subject: North America Language: English Journal: Harm Reduct J Year: 2021 Document Type: Article Affiliation country: S12954-021-00522-3